| Jun 19 |
FDA places partial clinical hold on Zentalis’ trials of azenosertib for cancer
|
| Jun 18 |
US Equity Markets Close Up Tuesday Following Less-Than-Expected Retail Sales Growth
|
| Jun 18 |
Top Midday Decliners
|
| Jun 18 |
Zentalis falls after FDA partial clinical hold on lead asset
|
| Jun 18 |
Zentalis Pharmaceuticals Provides Update on Azenosertib Clinical Development Program
|
| Jun 4 |
We Think Zentalis Pharmaceuticals (NASDAQ:ZNTL) Can Afford To Drive Business Growth
|
| Jun 1 |
Insider Selling at Zentalis Pharmaceuticals Inc (ZNTL): President, Interim CFO Cam Gallagher ...
|
| May 30 |
Zentalis Pharmaceuticals to Present at the Jefferies Global Healthcare Conference
|
| May 29 |
Zentalis Pharmaceuticals Announces Appointment of Accomplished Oncology Drug Developer Luke Walker, M.D., to Board of Directors
|
| May 23 |
Zentalis Pharmaceuticals to Present Promising Results from Phase 1 Trial of Azenosertib and Gemcitabine in Relapsed or Refractory Osteosarcoma at 2024 American Society of Clinical Oncology Annual Meeting
|
